Two Randomized Placebo-Controlled Clinical Studies Planned to Assess Subcutaneous Administration of VRDN-003, a Next-Generation Full Antagonist Antibody to IGF-1R, in Patients With Thyroid Eye Disease (TED), REVEAL-1 and REVEAL-2
You are now leaving the Viridian Therapeutics website.
You are about to leave the Viridian Therapeutics website for another external website. Viridian Therapeutics has no responsibility for the content of such other sites and is not liable for any damages or injury arising from that content. Any links to other sites are provided merely as a convenience to the users of this website.